Cornerstone Therapeutics (CRTX) is a specialty pharmaceutical company focused on products for hospitals and specialty markets. The company turned a profit early in its history, then went deep in the red acquiring products that fit its focus. In 2013, Cornerstone has come roaring back to profitability, and is one of the most exciting growth stories I've seen this year.
At the company's recent price of about $9.40, I see a near certain gain of at least 62% within a year, with a highly unlikely potential loss of 33%. I couldn't believe such a clearly undervalued company could be floating under our noses, until I realized just how many noses it was floating under. The Q2 2013 earnings call...
Only subscribers can access this article, which is part of the PRO research library covering 3,768 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: